Skip to main content

Table 10 Ongoing clinical trials of fibrinolytic therapy in COVID-19

From: Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations

NCT number

Study name

Interventions

Sponsor

NCT04357730

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

Phase 2a trial comparing 50 mg and 100 mg doses of alteplase

Denver Health and Hospital Authority (USA)

NCT04356833

Nebulised rtPA for ARDS Due to COVID-19 (PACA)

Phase 2 trial evaluation nebulized tissue plasminogen activator in COVID-19 ARDS

University College London (UK)

  1. Abbreviations: ARDS acute respiratory distress syndrome, COVID-19 coronavirus disease 2019, mg milligrams, Rt-PA recombinant tissue plasminogen activator
Back to article page

Critical Care

ISSN: 1364-8535